Mechanical Support in Myocardial Infarction Complicated by Cardiogenic Shock: What Have We Learned from Trials?

Area of Science:

• Cardiology
• Critical Care Medicine
• Cardiovascular Interventions

Background:

• Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI), carrying high mortality rates (40-50%) even with early revascularization.
• Temporary mechanical circulatory support (tMCS) devices, including intra-aortic balloon pump (IABP), microaxial flow pumps (MAFP), and veno-arterial extracorporeal membrane oxygenation (VA-ECMO), are used for refractory shock.
• Existing clinical trial data on tMCS efficacy in AMI-CS presents conflicting results and limited survival benefits, with significant disparities between trial populations and real-world clinical practice.

Purpose of the Study:

• To review the current evidence and clinical challenges associated with the use of temporary mechanical circulatory support (tMCS) in patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI).
• To emphasize the need for individualized patient selection and management strategies for tMCS in AMI-CS.
• To highlight the importance of structured shock systems and multidisciplinary teams in optimizing tMCS utilization and patient outcomes.

Main Methods:

• Review of existing randomized controlled trials (RCTs) and real-world data on tMCS devices (IABP, MAFP, VA-ECMO) in acute myocardial infarction complicated by cardiogenic shock.
• Analysis of trial inclusion criteria versus characteristics of the broader AMI-CS patient population.
• Discussion of clinical management considerations, including patient profiling, hemodynamic staging, neurological status, and the role of shock teams.

Main Results:

• The IABP-SHOCK II trial showed no mortality benefit for IABP in AMI-CS.
• The DanGer Shock trial indicated a potential survival benefit with MAFP (Impella CP) in highly selected patients.
• ECLS-SHOCK and ECMO-CS trials demonstrated no survival improvement with early VA-ECMO and reported high complication rates.

Conclusions:

• Current evidence for tMCS in AMI-CS is conflicting, with significant limitations in applying RCT findings to diverse real-world patient populations.
• High in-hospital mortality persists with conventional tMCS devices in clinical practice.
• Individualized, protocol-driven care within structured shock systems, guided by multidisciplinary teams, is essential to optimize tMCS selection and improve outcomes in heterogeneous AMI-CS patients.